HEICO Corp. 10-Q Summary: Period Ended July 31, 1996
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 31, 1996, and the nine-month period ended on that date. HEICO Corporation is a Florida-based manufacturer of jet engine replacement parts and other aerospace components. The reporting period is significantly impacted by the divestiture of its health care services segment, MediTek Health Corporation, which was sold on July 11, 1996.
Key Financial Metrics
| Metric | Nine Months Ended July 31, 1996 | Nine Months Ended July 31, 1995 | Three Months Ended July 31, 1996 | Three Months Ended July 31, 1995 |
|---|---|---|---|---|
| Net Sales | $22,979,000 | $18,690,000 | $8,059,000 | $6,904,000 |
| Net Income (Total) | $8,505,000 | $1,942,000 | $6,553,000 | $721,000 |
| Net Income (Continuing Ops) | $2,278,000 | $973,000 | $1,053,000 | $514,000 |
| Net Income Per Share (Total) | $1.60 | $0.41 | $1.18 | $0.15 |
| Operating Cash Flow | $3,599,000 | $4,590,000 | N/A | N/A |
| Cash and Equivalents (End Period) | $21,788,000 | $5,343,000 | N/A | N/A |
| Total Debt (Current + Long-term) | $3,138,000 | $7,870,000 | N/A | N/A |
| Gross Margin (9 Months) | 34.5% | 31.6% | 35.9% (Q3) | 31.9% (Q3) |
Material Changes vs. Prior Period
- Divestiture of Health Care Segment: The Company sold MediTek Health Corporation for $13.8 million in cash and a $10 million convertible note. This transaction generated a one-time gain of $5.264 million, which is the primary driver of the 338% increase in total net income for the nine-month period.
- Continuing Operations Growth: Excluding the discontinued operations, net income from continuing operations increased 134% year-over-year for the nine-month period, driven by a 23% increase in net sales and improved gross margins.
- Liquidity Improvement: Cash and cash equivalents increased from $4.7 million to $21.8 million, largely due to proceeds from the MediTek sale and the maturity of short-term investments.
- Debt Reduction: Total debt decreased significantly from approximately $7.9 million to $3.1 million, reflecting debt repayments and the restructuring of liabilities associated with the MediTek sale.
Outlook, Risks, and Management Commentary
- Backlog: Order backlog stood at approximately $19 million as of July 31, 1996, up from $15.5 million a year prior but down from $23 million at the start of the fiscal year. Management attributes the year-over-year increase to higher demand and sales incentives.
- Margin Expansion: Gross profit margins improved to 34.5% (9 months) and 35.9% (Q3) due to favorable product mix and manufacturing cost reductions.
- Convertible Note Liquidity: The $10 million note received from the buyer (USDL) is convertible into USDL stock. USDL has agreed to prepay the note upon request until the stock is registered, providing liquidity assurance. Registration is targeted for effectiveness by January 1, 1997.
- Stock Dividends: The Company executed a 3-for-2 stock split in April 1996 and a 10% stock dividend in July 1996. All per-share data in the filing has been restated to reflect these actions.
- Risks: The filing notes that results for the nine months ended July 31, 1996, are not necessarily indicative of full-year results. There are no material legal proceedings reported.
Investor Verification Checklist
- Gain on Sale: Verify the $5.264 million gain on the MediTek sale is classified correctly as a discontinued operation and does not inflate recurring earnings expectations.
- Convertible Note Terms: Confirm the status of the $10 million USDL note and the timeline for the registration of the underlying shares to ensure liquidity options remain valid.
- Backlog Quality: Assess the composition of the $19 million backlog, specifically the portion based on "forecasted shipments" versus firm orders, given the recent decline from the October 1995 peak.
- Inventory Build: Review the $1.2 million increase in inventory, which contributed to a decline in operating cash flow, to ensure it aligns with the stated strategy of meeting customer delivery requirements.
- Stock Split Impact: Ensure all historical per-share comparisons account for the 3-for-2 split and subsequent 10% dividend to avoid valuation errors.